Positive but expected
• Bayer gets FDA approval for elinzanetant in women's health.
• Street estimates for peak sales have been around $1.2bn which would be around 6.7% of current pharma earnings.
• Bayer's main competitor will be Astellas's Veozah which estimates peak sales at $3.6bn for it's treatment.
Find more articles and bullets on these widgets:
While we heard the monetary policy views of 6 of 12 current FOMC voters this week, there were no real surprises. We go through all of the relevant FOMC communications in full in our Macro Weekly PDF.
2025 FOMC Voters:
Non-2025 Voters:
We've just published our US Macro Weekly - Download Full Report Here
